Most Oral Blood Cancer Drugs Rejected by Insurers
In a study of 12,134 patients, insurers rejected most first-time oral blood cancer prescriptions, and many approved ones went unfilled.
Updated on Nov. 2, 2026 in Cancer
Live Poll
Do you trust your health insurer to approve and cover prescribed medications fairly?
Most specialty oral blood cancer prescriptions are rejected by U.S. insurers on first submission, according to a nationwide claims study of 12,134 Medicare and commercially insured patients who started a new prescription in 2022. Many of the prescriptions that were eventually approved were never filled, largely because of out-of-pocket costs.
Why it matters
For people with blood cancers taking pills rather than infusions, a delayed or unfilled prescription can mean a gap in treatment that affects disease control. The findings suggest that access problems at the pharmacy counter are a meaningful barrier to care, not just a billing inconvenience.
This is a claims-based analysis of 12,134 patients who received new specialty oral anticancer prescriptions for blood cancers in 2022, comparing Medicare and commercially insured groups. The figures describe real-world pharmacy claims rather than a clinical trial, and the cap's effect on fill rates is a projection not yet measured.
The players
Perelman School of Medicine at the University of Pennsylvania
A leading academic medical school whose researchers led the study of oral blood cancer drug access.
MD Anderson Cancer Center
A major National Cancer Institute-designated cancer center in Houston that contributed researchers to the study.
Blood Cancer United
A patient advocacy organization, formerly the Leukemia & Lymphoma Society, that funded the study.
The details
Most initial rejections were driven by prior authorization requirements and formulary restrictions, which are insurer rules that require approval or limit coverage to preferred drugs. Commercially insured patients had more than three times the adjusted odds of rejection compared with Medicare beneficiaries. Medicare Part D treats anticancer drugs as a protected class that plans must cover, while commercial insurers face no equivalent federal requirement.
Timeline
Prescriptions tracked in the study were started in 2022.
Medicare's $2,100 annual out-of-pocket cap took effect in 2026.
The CMS prior authorization rule took effect in 2026 and excludes prescription drugs.
Health Landscape
The gap between Medicare Part D and commercial coverage of oral cancer drugs reflects a federal protected-class mandate that commercial insurers do not share. Medicare's 2026 out-of-pocket cap is the next major policy test of whether cost barriers to these oral therapies can be reduced.
If you or a family member has a new oral cancer prescription, it is worth asking your care team early whether the drug will need prior authorization and what the out-of-pocket cost will be before the first fill. Talk with your doctor about options if cost threatens to delay treatment.
The takeaway
Most rejections were fixable with prior authorization and coverage steps, so ask your pharmacy and doctor to check coverage before starting an oral cancer drug. If cost is a barrier, raise it with your care team promptly rather than letting a prescription sit unfilled.
Further reading
Explore more on the Cancer section for context on treatment access across the United States.
Source note: This article includes information reported by Insurance Business.
Live Poll
Do you trust your health insurer to approve and cover prescribed medications fairly?
